Author

D. Ribaldone

View on Semantic Scholar

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Effect of JAK inhibitors on extraintestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease.

M. Truyens, X. Tolstoy, G. Calabrese et al. · Journal of Crohn's & Colitis · 0 citations

Open access Sep 2026

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease-A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD).

BACKGROUND AND AIMS Upadacitinib is an oral selective JAK1 inhibitor approved for moderate-to-severe Crohn's disease (CD), but real-world prospective multicentre data in advanced therapy-experienced (AT-experienced) patients are limited. The UPGRADE-CD study evaluated its effectiveness and safety. METHODS In this pro...

B. Barberio, F. D'Amico, L. Laterza et al. · Alimentary Pharmacology and... · 0 citations